DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor
DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic
strategy, the interaction of tumor DNA damage with the immune system has recently come
into focus, and it is now clear that the tumor DNA repair landscape has an important role in
driving response to immune checkpoint blockade. Here, we summarize the mechanisms by
which DNA damage and genomic instability have been found to shape the antitumor …